Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364321001065 |
| _version_ | 1818751659316084736 |
|---|---|
| author | Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD |
| author_facet | Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD |
| author_sort | Lise Bertin, MD |
| collection | DOAJ |
| description | In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of patients with HIV suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here, we report the largest known study of patients with HIV with NSCLC (five patients) undergoing first-line immunotherapy by pembrolizumab, after CANCERVIH group selection. Our results are consistent with those of previous case reports concerning safety of immunotherapy in patients with HIV, revealing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome. Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also evaluated the effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients having rapid progression and two partial response. Nevertheless, besides safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV needs to be supported by larger studies. |
| first_indexed | 2024-12-18T04:39:05Z |
| format | Article |
| id | doaj.art-ec6f4644ae4240f5bb7de65702a720dc |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-12-18T04:39:05Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-ec6f4644ae4240f5bb7de65702a720dc2022-12-21T21:20:46ZengElsevierJTO Clinical and Research Reports2666-36432021-11-01211100247Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC TherapyLise Bertin, MD0Anthony Canellas, MD1Baptiste Abbar, MD2Marianne Veyri3Jean-Philippe Spano, MD, PhD4Jacques Cadranel, MD, PhD5Armelle Lavolé, MD6Service de Pneumologie et Oncologie Thoracique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, FranceService de Pneumologie et Oncologie Thoracique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; GRC 04 Theranoscan, Sorbonne Université, Paris, FranceDepartment of Medical Oncology, Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; Institut Universitaire de Cancérologie, CLIP2 Galilée, Paris, FranceDepartment of Medical Oncology, Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; Institut Universitaire de Cancérologie, CLIP2 Galilée, Paris, France; Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université, Paris, FranceDepartment of Medical Oncology, Pitié Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; Institut Universitaire de Cancérologie, CLIP2 Galilée, Paris, France; Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université, Paris, FranceService de Pneumologie et Oncologie Thoracique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; GRC 04 Theranoscan, Sorbonne Université, Paris, FranceService de Pneumologie et Oncologie Thoracique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France; GRC 04 Theranoscan, Sorbonne Université, Paris, France; Corresponding author. Address for correspondence: Armelle Lavolé, MD, Service de Pneumologie et Oncologie Thoracique, Hopital Tenon, Assistance Publique-Hopitaux de Paris (APHP), Paris, France.In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clinical trials, and up-to-date recommendations for these patients are lacking. Only few cases of patients with HIV suffering from cancer and undergoing first-line immunotherapy have been reported so far. Here, we report the largest known study of patients with HIV with NSCLC (five patients) undergoing first-line immunotherapy by pembrolizumab, after CANCERVIH group selection. Our results are consistent with those of previous case reports concerning safety of immunotherapy in patients with HIV, revealing no severe or fatal toxicity, opportunistic infections, or immune reconstitution inflammatory syndrome. Moreover, pembrolizumab did not seem to modify HIV viral parameters. We also evaluated the effectiveness of immunotherapy in these HIV-immunosuppressed patients: the average survival was 9.8 months, with three patients having rapid progression and two partial response. Nevertheless, besides safety and drug-to-drug interactions, the effectiveness of first-line immunotherapy in people living with HIV needs to be supported by larger studies.http://www.sciencedirect.com/science/article/pii/S2666364321001065HIVAnti–PD-1CD4+Viral loadLung cancer |
| spellingShingle | Lise Bertin, MD Anthony Canellas, MD Baptiste Abbar, MD Marianne Veyri Jean-Philippe Spano, MD, PhD Jacques Cadranel, MD, PhD Armelle Lavolé, MD Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy JTO Clinical and Research Reports HIV Anti–PD-1 CD4+ Viral load Lung cancer |
| title | Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy |
| title_full | Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy |
| title_fullStr | Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy |
| title_full_unstemmed | Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy |
| title_short | Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy |
| title_sort | brief report of anti programmed cell death protein 1 in human immunodeficiency virus setting relevant and breaking results in first line nsclc therapy |
| topic | HIV Anti–PD-1 CD4+ Viral load Lung cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2666364321001065 |
| work_keys_str_mv | AT lisebertinmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT anthonycanellasmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT baptisteabbarmd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT marianneveyri briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT jeanphilippespanomdphd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT jacquescadranelmdphd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy AT armellelavolemd briefreportofantiprogrammedcelldeathprotein1inhumanimmunodeficiencyvirussettingrelevantandbreakingresultsinfirstlinensclctherapy |